Newborns in the neonatal intensive care unit (NICU) often face severe, life-threatening conditions. For some, extracorporeal membrane oxygenation (ECMO) serves as a crucial therapy, temporarily taking over heart and lung function when these organs are unable to perform effectively. In a six-year study conducted at a specialized children’s hospital (Rady Children’s Hospital, San Diego), researchers examined the impact of rapid (rWGS) and ultra-rapid whole genome sequencing (urWGS) in guiding care for these critically ill infants.
Study Parameters and Population
The study reviewed NICU cases requiring ECMO between May 2017 and September 2023. Among 39 eligible neonates, 26 (72%) underwent rWGS or urWGS testing. Sequencing was timed before, during, or shortly after ECMO treatment, with decisions informed by clinical trials and consultations with genetics specialists. Turnaround times for urWGS averaged three days, compared to five days for rWGS.
Genetic Testing and Its Outcomes
Testing revealed a phenotype-linked diagnosis in 12 of 26 cases (46%). These findings informed clinical decisions in nearly 40% of tested patients, demonstrating practical applications such as avoiding invasive procedures and guiding therapy. Cases where testing results were negative also contributed to management, including bypassing unnecessary diagnostic interventions. The conditions identified included congenital diaphragmatic hernia, persistent pulmonary hypertension, and uncommon metabolic disorders. Patients with metabolic conditions were especially likely to benefit, reflecting the genetic basis of many ECMO-associated diagnoses.
Clinical Utility and Decision-Making
For patients requiring ECMO, rWGS and urWGS provided actionable insights. For example, one patient with a prenatal diagnosis of LADD (lacrimo-auriculo-dento-digital) syndrome avoided a lung biopsy due to confirming test results. Another patient diagnosed with methylmalonic acidemia was placed on a specialized metabolic diet following testing.
Limitations and Future Directions
While the study highlights rWGS and urWGS as valuable diagnostic tools, it acknowledges limitations, including challenges in retrospective data analysis and assessing the utility of negative results. Variability in sequencing use, influenced by illness severity, also underscored the need for further research. Prospective studies could clarify when to prioritize these technologies, especially as urWGS becomes more widely accessible. However, the ability of rWGS and urWGS to rapidly diagnose genetic conditions is a significant advancement in neonatal care that offers value for critically ill ECMO patients. Their optimal integration into clinical workflows is an important area for continued exploration.
Publication Details
Amin, M.D., Wigby, K., Suttner, D. et al. Clinical utility of rapid whole genome sequencing in neonatal patients receiving extracorporeal membrane oxygenation (ECMO). J Perinatol (2024). https://doi.org/10.1038/s41372-024-02181-1
Study Parameters and Population
The study reviewed NICU cases requiring ECMO between May 2017 and September 2023. Among 39 eligible neonates, 26 (72%) underwent rWGS or urWGS testing. Sequencing was timed before, during, or shortly after ECMO treatment, with decisions informed by clinical trials and consultations with genetics specialists. Turnaround times for urWGS averaged three days, compared to five days for rWGS.
Genetic Testing and Its Outcomes
Testing revealed a phenotype-linked diagnosis in 12 of 26 cases (46%). These findings informed clinical decisions in nearly 40% of tested patients, demonstrating practical applications such as avoiding invasive procedures and guiding therapy. Cases where testing results were negative also contributed to management, including bypassing unnecessary diagnostic interventions. The conditions identified included congenital diaphragmatic hernia, persistent pulmonary hypertension, and uncommon metabolic disorders. Patients with metabolic conditions were especially likely to benefit, reflecting the genetic basis of many ECMO-associated diagnoses.
Clinical Utility and Decision-Making
For patients requiring ECMO, rWGS and urWGS provided actionable insights. For example, one patient with a prenatal diagnosis of LADD (lacrimo-auriculo-dento-digital) syndrome avoided a lung biopsy due to confirming test results. Another patient diagnosed with methylmalonic acidemia was placed on a specialized metabolic diet following testing.
Limitations and Future Directions
While the study highlights rWGS and urWGS as valuable diagnostic tools, it acknowledges limitations, including challenges in retrospective data analysis and assessing the utility of negative results. Variability in sequencing use, influenced by illness severity, also underscored the need for further research. Prospective studies could clarify when to prioritize these technologies, especially as urWGS becomes more widely accessible. However, the ability of rWGS and urWGS to rapidly diagnose genetic conditions is a significant advancement in neonatal care that offers value for critically ill ECMO patients. Their optimal integration into clinical workflows is an important area for continued exploration.
Publication Details
Amin, M.D., Wigby, K., Suttner, D. et al. Clinical utility of rapid whole genome sequencing in neonatal patients receiving extracorporeal membrane oxygenation (ECMO). J Perinatol (2024). https://doi.org/10.1038/s41372-024-02181-1